Trifluperidol
Trifluperidol.svg
Clinical data
Trade namesTriperidol
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Identifiers
  • 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23F4NO2
Molar mass409.425 g·mol−1
3D model (JSmol)
  • FC(F)(F)c1cccc(c1)C3(O)CCN(CCCC(=O)c2ccc(F)cc2)CC3
  • InChI=1S/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2 checkY
  • Key:GPMXUUPHFNMNDH-UHFFFAOYSA-N checkY

Trifluperidol is a typical antipsychotic of the butyrophenone chemical class. It has general properties similar to those of haloperidol, but is considerably more potent by weight, and causes relatively more severe side effects, especially tardive dyskinesia and other extrapyramidal effects. It is used in the treatment of psychoses including mania and schizophrenia. It was discovered at Janssen Pharmaceutica in 1959.[1][2]

Synthesis

Trifluperidol Synthesis:[3] P. Adriaan J. Janssen, U.S. Patent 3,438,991 (1969).
Trifluperidol Synthesis:[3] P. Adriaan J. Janssen, U.S. Patent 3,438,991 (1969).

See also

References

  1. ^ Gallant DM, Bishop MP, Timmons E, Steele CA (September 1963). "A controlled evaluation of Trifluperidol: a new potent psychopharmacologic agent". Current Therapeutic Research, Clinical and Experimental. 5: 463–71. PMID 14065098.
  2. ^ Gallant DM, Bishop MP, Timmons E, Steele CA (November 1963). "Trifluperidol: a butyrophenone derivative". The American Journal of Psychiatry. 120 (5): 485–7. doi:10.1176/ajp.120.5.485. PMID 14051242.
  3. ^ GB 895309, Janssen, Paul Adriaan Jan, "Pyrrolidine and piperidine derivatives", published 1962-05-02, assigned to N.V. Research Laboratorium Dr. C. Janssen